Situation: A 34-year-old man was diagnosed with human immunodeficiency virus (HIV) infection 1 week ago and has enrolled at a Department of Health (DOH)–accredited treatment hub, where he starts the once-daily tenofovir–lamivudine–dolutegravir (TLD) tablet today. His CD4 count is 150 cells/mm³, he has never had an opportunistic illness, and he has no drug allergies. Six months later, HIV RNA can no longer be found in his blood. Which statement by the client shows correct understanding of his treatment?

Undetectable = untransmittable: a person on antiretroviral therapy with a sustained undetectable viral load does not transmit HIV sexually. Treatment is lifelong; stopping or skipping doses allows viral rebound and drug resistance. Viral load is still checked regularly to confirm that suppression continues.

Core concept: U=U and lifelong ART

The correct statement is “If my viral load stays suppressed, I won’t pass it on through sex.” This reflects the U=U principle—a person on antiretroviral therapy with a sustained undetectable viral load does not transmit HIV sexually. The term “undetectable” means the viral load is below the assay’s detection limit, not that the virus has been eradicated. The client’s HIV RNA is no longer found in blood because the TLD regimen is suppressing viral replication, but latent reservoirs remain in lymphoid tissue and other compartments.

Key point! Undetectable does not mean cured. The virus is still present in the body, so ART must continue lifelong. Stopping or skipping doses allows rapid viral rebound and creates selection pressure for drug-resistant strains.

Why the other options are incorrect

Option 1 — “I can stop taking TLD now that the virus is gone from my blood” is wrong because viral suppression is not viral eradication. The blood test cannot detect virus below the assay threshold, but replication-competent virus persists. Discontinuation leads to viral rebound within weeks.

Option 2 — “I can take TLD every other day” is dangerous. TLD is a once-daily fixed-dose combination. Skipping doses reduces drug concentrations below the inhibitory threshold, allowing viral replication and emergence of resistance mutations. Dolutegravir has a relatively high barrier to resistance, but tenofovir and lamivudine are more vulnerable when adherence is poor.

Option 4 — “I no longer need viral load tests” is incorrect. Viral load monitoring remains essential even after suppression to confirm that suppression continues and to detect virologic failure early. Guidelines recommend regular viral load testing—typically every 6 to 12 months in stable, suppressed patients—to catch rebound before clinical deterioration or resistance develops.

Evidence from the literature

The Uganda-based mixed-methods study examined adherence to viral load testing guidelines in routine HIV clinics . It highlights that viral load testing is the standard tool for monitoring treatment success and detecting virologic failure, and that gaps in testing adherence can delay identification of patients who need adherence support or regimen change. This reinforces why option 4 is wrong: even with an undetectable result, ongoing monitoring is a core component of care.

The scoping review and Delphi consensus on low-level viraemia underscores that viral load thresholds matter. Persistent low-level viraemia—commonly defined as repeated viral loads between 50 and 1000 copies/mL—is associated with heterogeneous outcomes and requires careful management. This shows that viral load is not a binary “gone or not gone” measure; clinicians must track trends over time. A single undetectable reading does not eliminate the need for future testing.

The systematic review by Bonner et al. examined viral load monitoring as a tool to reinforce adherence. It found that receiving viral load results can motivate patients to maintain adherence, and that elevated viral loads can prompt intensified counseling. This supports the idea that viral load testing has both diagnostic and behavioral roles—another reason it cannot be discontinued after suppression.

The meta-analysis on maternal viral load and vertical transmission explicitly notes that a growing body of evidence supports zero risk of sexual HIV transmission from a person with sustained virological suppression, known as U=U. While that paper focuses on vertical transmission, its framing confirms that U=U is now an accepted, evidence-based principle for sexual transmission. This directly validates option 3 as the correct understanding.

Clinical application for nursing practice

When educating a client starting TLD, the nurse should emphasize three linked messages: ART is lifelong, adherence must be near-perfect, and viral load testing continues indefinitely. The client’s CD4 count of 150 cells/mm³ places him at risk for opportunistic infections, so adherence and monitoring are especially critical. A sustained undetectable viral load protects sexual partners, but it does not protect against other sexually transmitted infections, so condom use may still be discussed for STI prevention. However, for HIV transmission specifically, U=U means the risk through sex is effectively zero when suppression is maintained and confirmed by regular testing.